Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New and Emerging Systemic Treatments for Atopic Dermatitis
Megan Newsom, Arjun M. Bashyam, Esther A. Balogh, et al.
Drugs (2020) Vol. 80, Iss. 11, pp. 1041-1052
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

Conjunctivitis in dupilumab clinical trials
Bolanle Akinlade, Emma Guttman‐Yassky, Marjolein de Bruin‐Weller, et al.
British Journal of Dermatology (2019) Vol. 181, Iss. 3, pp. 459-473
Open Access | Times Cited: 355
Pathogenesis of allergic diseases and implications for therapeutic interventions
Ji Wang, Yumei Zhou, Honglei Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 138
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
Hideyuki Ujiie, David Rosmarin, Michael P. Schön, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 112
Photo-responsive polydopamine nanoenzyme microneedles with oxidative stress regulation ability for atopic dermatitis treatment
Yuanyuan Zhang, Xiao‐Xuan Zhang, Xiangyi Wu, et al.
Nano Today (2024) Vol. 56, pp. 102241-102241
Closed Access | Times Cited: 16
OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
Ana Maria Lé, Tiago Torres
Pharmaceutics (2022) Vol. 14, Iss. 12, pp. 2753-2753
Open Access | Times Cited: 48
The role of Janus kinase signaling in the pathology of atopic dermatitis
Emma Guttman‐Yassky, Alan D. Irvine, Patrick M. Brunner, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 6, pp. 1394-1404
Open Access | Times Cited: 34
Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice
Anne R. Schlösser, Madena Shareef, Jill I. Olydam, et al.
Clinical and Experimental Dermatology (2023) Vol. 48, Iss. 5, pp. 510-517
Open Access | Times Cited: 25
Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study
Axel De Greef, Pierre‐Dominique Ghislain, Audrey Bulinckx, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 4, pp. 299-306
Open Access | Times Cited: 23
Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment
Yoav Nahum, Michael Mimouni, Eitan Livny, et al.
British Journal of Ophthalmology (2019) Vol. 104, Iss. 6, pp. 776-779
Closed Access | Times Cited: 64
Systemic treatments for eczema: a network meta-analysis
Ratree Sawangjit, Piyameth Dilokthornsakul, Antonia Lloyd-Lavery, et al.
Cochrane library (2020) Vol. 2020, Iss. 9
Open Access | Times Cited: 56
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials
Jonathan I. Silverberg, Eric L. Simpson, Marius Ardeleanu, et al.
British Journal of Dermatology (2019) Vol. 181, Iss. 1, pp. 80-87
Open Access | Times Cited: 56
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
Xiaohua Gong, Xuejun Chen, Michael E. Kuligowski, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 4, pp. 555-566
Open Access | Times Cited: 53
Interleukin-31 and Pruritic Skin
Masutaka Furue, Mihoko Furue
Journal of Clinical Medicine (2021) Vol. 10, Iss. 9, pp. 1906-1906
Open Access | Times Cited: 41
Atopic dermatitis: treatment and innovations in immunotherapy
Francesco Ferrara, Andrea Zovi, Maurizio Capuozzo, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 3, pp. 1777-1789
Closed Access | Times Cited: 7
Role of antioxidants supplementation in the treatment of atopic dermatitis: a critical narrative review
Edoardo De Simoni, Matteo Candelora, Sara Belleggia, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 6
Tralokinumab: First Approval
Sean T. Duggan
Drugs (2021) Vol. 81, Iss. 14, pp. 1657-1663
Open Access | Times Cited: 38
Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
Chenyang Li, Xun Sun, Kun Zhao, et al.
Dermatology (2021) Vol. 238, Iss. 4, pp. 725-735
Open Access | Times Cited: 34
Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
Sheridan M. Hoy
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 3, pp. 409-420
Open Access | Times Cited: 24
Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab
Angela J. Okragly, Aya Ryuzoji, Isabella H. Wulur, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 7, pp. 1535-1547
Open Access | Times Cited: 15
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, et al.
Dermatology and Therapy (2025)
Open Access
Mesenchymal Stromal Cell-Derived Extracellular Vesicles in the Management of Atopic Dermatitis: A Scoping Review of Therapeutic Opportunities and Challenges
Maimonah Eissa Al-Masawa, Loai A. Elfawy, Chiew Yong Ng, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 2673-2693
Open Access
A novel anti-OX40 human monoclonal antibody that blocks OX40/OX40L signaling and depletes OX40+ T cells
Zhen Li, Lin Liu, Xiaobo Chen, et al.
Marine Life Science & Technology (2025)
Open Access
Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases
Maria C. Schneeweiss, Seoyoung C. Kim, Richard Wyss, et al.
JAMA Dermatology (2021) Vol. 157, Iss. 7, pp. 805-805
Open Access | Times Cited: 28
A new era of atopic eczema research: Advances and highlights
Claudia Hülpüsch, Andreas Benedikt Weins, Claudia Traidl‐Hoffmann, et al.
Allergy (2021) Vol. 76, Iss. 11, pp. 3408-3421
Open Access | Times Cited: 27
Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
Angelina Labib, Teresa Ju, Gil Yosipovitch
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 1065-1072
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top